Health & Life Co., Ltd. AI Stock Analysis
Health & Life Co., Ltd. (1781) AI Stock Analysis
Health & Life Co., Ltd.
(TPEx:1781)
The score is driven primarily by deteriorating financial performance: a 44% revenue decline, a swing back into operating and net losses, margin compression and negative free cash flow, with only a moderately leveraged but steadily eroding balance sheet providing a cushion. Technicals reinforce the caution, with the price below all key moving averages and negative MACD signalling a firm downtrend, though oversold RSI and Stochastic readings suggest the selling may be extended. Valuation adds no support, as the negative P/E reflects ongoing losses and there is no dividend to compensate investors. Stabilisation in revenue and a sustained gross margin recovery would be the key signals of improvement.
Health & Life Co., Ltd. (1781) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 407.71M
- Dividend Yield
- ―
- Average Volume (3M)
- 44.63K
- Price to Earnings (P/E)
- -8.0
- Beta (1Y)
- 0.43
- Revenue Growth
- -12.12%
- EPS Growth
- -17.29%
- Country
- TW
- Employees
- 120
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Health & Life Co., Ltd. Business Overview & Revenue Model
Company Description
Health & Life Co., Ltd. is a global provider of medical devices. Established in 1996 and headquartered in New Taipei City, Taiwan, the company specializes in developing and distributing solutions for critical health sectors, including cardiovascular...
Health & Life Co., Ltd. Financial Statement Overview
Summary
Health & Life's financial profile is weak. Revenue collapsed roughly 44% to about NT$398 million, erasing 2024's recovery and pushing the company back to an operating loss of NT$63.4 million and a net loss of NT$61.7 million, with gross margin compressing to 17.6%. Cash generation is the weakest link: operating cash flow was a token NT$3.2 million and free cash flow turned negative, following several years of heavy burn. The balance sheet remains the main cushion, with equity funding about 44% of assets and debt-to-equity of 0.61, but leverage is rising while equity and total assets have steadily eroded since 2020. Losses in four of the past six years point to a turnaround that has yet to take hold.
Income Statement
24NegativeBalance Sheet
47NeutralCash Flow
29Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 400.09M | 398.05M | 706.39M | 601.17M | 797.54M | 811.88M |
| Gross Profit | 52.62M | 70.12M | 147.74M | 93.11M | 97.72M | 45.76M |
| EBITDA | -31.11M | -46.70M | 55.63M | -7.84M | 11.85M | -63.05M |
| Net Income | -50.67M | -61.67M | 24.24M | -33.23M | -17.55M | -62.34M |
Balance Sheet | ||||||
| Total Assets | 655.77M | 723.13M | 817.26M | 710.79M | 799.76M | 776.39M |
| Cash, Cash Equivalents and Short-Term Investments | 222.42M | 247.94M | 277.35M | 151.05M | 156.98M | 200.32M |
| Total Debt | 198.03M | 196.97M | 214.14M | 113.60M | 189.45M | 134.81M |
| Total Liabilities | 352.54M | 402.56M | 424.21M | 375.42M | 427.18M | 398.22M |
| Stockholders Equity | 303.23M | 320.57M | 393.05M | 335.37M | 372.58M | 378.18M |
Cash Flow | ||||||
| Free Cash Flow | -25.33M | -5.01M | 30.14M | 76.82M | -93.02M | -145.04M |
| Operating Cash Flow | -16.54M | 3.18M | 33.35M | 84.91M | -80.69M | -131.15M |
| Investing Cash Flow | 41.19M | 41.96M | -89.81M | -8.78M | -10.32M | -16.02M |
| Financing Cash Flow | -15.78M | -21.91M | 128.68M | -74.67M | 25.91M | -91.10M |
Health & Life Co., Ltd. Peers Comparison
Overall Rating
- TW:178135Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:1781 | 35Underperform | TWD 407.71M | -8.04 | ― | ― | -12.12% | -17.29% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1781 | Health & Life Co., Ltd. | 8.60 | -3.40 | -28.33% | |
| TW:4115 | Sunder Biomedical Tech. Co., Ltd. | 6.97 | -1.43 | -17.02% | |
| TW:4117 | General Biologicals Corp. | 7.41 | -5.04 | -40.48% | |
| TW:4186 | Taiwan Advance Bio-Pharmaceutical, Inc. | 7.00 | -6.00 | -46.15% | |
| TW:6549 | TaiwanJ Pharmaceuticals Co., Ltd. | 6.25 | -1.47 | -19.04% | |
| TW:6621 | Unipharma Co., Ltd. | 12.00 | -0.35 | -2.83% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026